By identifying six somatic driver mutations of EGFR, KRAS, TP53, BRAF, PIK3CA, and ERBB2 through targeted sequencing utilizing the SV-CA50-ctDNA panel (San Valley Biotech Inc., Beijing, China), Guo et al. reported the changes in tumor and blood ctDNA levels in 41 NSCLC patients before and after surgery. This evidence concerns the gene KRAS and neoplasm.